| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1582 | 2016 |
| Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis H Nozawa, C Chiu, D Hanahan Proceedings of the National Academy of Sciences 103 (33), 12493-12498, 2006 | 1023 | 2006 |
| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 971 | 2018 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 911 | 2019 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 872 | 2019 |
| Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ... Blood, The Journal of the American Society of Hematology 130 (8), 974-981, 2017 | 497 | 2017 |
| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 366 | 2016 |
| Requirement for B cell linker protein (BLNK) in B cell development R Pappu, AM Cheng, B Li, Q Gong, C Chiu, N Griffin, M White, ... Science 286 (5446), 1949-1954, 1999 | 347 | 1999 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 295 | 2018 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 248 | 2020 |
| Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, ... haematologica 103 (12), 2088, 2018 | 236 | 2018 |
| Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... The Lancet 398 (10306), 1157-1169, 2021 | 213 | 2021 |
| A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens H Pere, Y Montier, J Bayry, F Quintin-Colonna, N Merillon, E Dransart, ... Blood, The Journal of the American Society of Hematology 118 (18), 4853-4862, 2011 | 196 | 2011 |
| Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ... Blood advances 1 (23), 2105-2114, 2017 | 193 | 2017 |
| BLNK: molecular scaffolding through ‘cis’‐mediated organization of signaling proteins CW Chiu, M Dalton, M Ishiai, T Kurosaki, AC Chan The EMBO journal, 2002 | 181 | 2002 |
| Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial C Thieblemont, T Phillips, H Ghesquieres, CY Cheah, MR Clausen, ... Journal of Clinical Oncology 41 (12), 2238-2247, 2023 | 174 | 2023 |
| Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab J Krejcik, KA Frerichs, IS Nijhof, B van Kessel, JF van Velzen, AC Bloem, ... Clinical cancer research 23 (24), 7498-7511, 2017 | 172 | 2017 |
| Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR MV Mateos, P Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 509-518, 2020 | 134 | 2020 |
| High‐parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action HC Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Smets, J Bald, ... Cytometry Part A 95 (3), 279-289, 2019 | 126 | 2019 |
| Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical … CW Chiu, H Nozawa, D Hanahan Journal of Clinical Oncology 28 (29), 4425, 2010 | 121 | 2010 |
